May 2, 2024 – More than 1 million Americans with Crohn’s, a chronic and sometimes crippling inflammatory bowel disease that affects the intestines and leads to digestive issues. While some people may have mild symptoms even be symptom-free at times, others get severe belly pain, diarrhea, fatigue, weight loss, anemia, and other life-threatening complications.
So far, the condition doesn’t have a cure, and treatments are often limited. Typical drugs to treat it, such as steroids and immunosuppressants, can provide relief and slow the disease’s progress, but many patients say the drugs don’t work as well over time don’t respond at all. Although surgery may be an option quanto a some cases, both patients and doctors eagerly aspetto for new therapies that can help relieve symptoms and also lead to a better quality of life.
A causa di recent years, gastrointestinal researchers have sharply focused acceso solutions for IBD overall and Crohn’s quanto a particular. As research dollars have flowed quanto a, GI experts across the U.S. have tested new medications that target inflammation and autoimmune reactions, as well as fecal transplants that can transfer “good” bacteria from a donor’s digestive system to help improve gut .
A causa di 2024 ala, several developments have been announced that could bring relief quanto a different ways. A causa di California, for instance, researchers are developing a type of stem cell therapy that may help heal the intestinal lining and prompt a positive response from the franco system. The therapy has shown promising results quanto a mouse models but still needs to be tested quanto a human clinical trials. But it could provide an avenue for patients who don’t respond well to regolare treatments the latest medications.
“A causa di the last 10 years, a lot of new therapies and biologics have been expanded for IBD, but these medications with a risk of side effects, and at best, half of the patients don’t have a response. And if they have a response, the longer they’signore acceso the medications, the more likely they are to lose that response,” said Maneesh Dave, MD, an associate professor of medicine quanto a gastroenterology and hepatology at the University of California, Davis.
Studying Stem Cells
Dave, who leads the stem cell therapy research at UC Davis, pointed to other issues with current medications. Severe side effects can create blood clots quanto a the heart, lungs, and legs. These drugs often suppress the franco system, which can lead to a higher risk of infections and even cancer. That’s why Dave and others are working acceso solutions to increase response rates, sopravvissuto side effects, and get as close to remission as possible by treating inflammation and healing the gut.
A causa di a study published quanto a January quanto a npj Regenerative Medicine, Dave and colleagues studied how cells called human bone marrow-derived mesenchymal stem cells (hMSCs) can heal inflammation quanto a mice that have a type of chronic small intestine inflammation that resembles Crohn’s quanto a humans. When given the hMSCs, the mice had mucosal healing and an immunologic response – even weeks after the hMSCs were mai longer present.
“These cells can suppress the franco system and result quanto a regeneration of the intestinal lining, which is quite promising,” Dave said. “There’s a precedent for this quanto a Europe, where the cells are already approved for treatment of specific conditions, but we don’t have proof for that quanto a the U.S. yet, and clinical trials are ongoing.”
As these types of studies continue, Dave cautioned IBD patients against going to unregulated stem cell clinics, which offer therapies that aren’t yet proven. The FDA hasn’t approved any treatments quanto a this luogo, so stem cell offers are “still experimental” quanto a the U.S., he said, and could lead to infections other serious complications.
Feeling the Brillamento-Up
When people with Crohn’s disease have flare-ups, they often report belly pain, diarrhea, and sometimes stool with blood mucus. This shift quanto a symptoms means there’s inflammation quanto a the – and it needs healing. At Northwestern University, a team of scientists have developed a wireless implantable temperature sensor to detect these inflammatory flare-ups, with the hope of preventing limiting the damage.
“Changes quanto a temperature are a hallmark sign of inflammation, and prolonged inflammation can cause extensive damage to that tissue organ, which may lead to eventual whole-system disruption,” said Arun Sharma, PhD, a research associate professor of urology at Northwestern’s Feinberg School of Medicine and a research associate professor of biomedical engineering at the McCormick School of Engineering.
A causa di a study published quanto a March quanto a Nature Biomedical Engineering, Sharma and colleagues tested whether a temperature sensor – a tiny, soft device that rests against the intestines – could provide real-time insights about disease progression and flare-ups quanto a mice with Crohn’s disease. The researchers used the sensors to continuously track changes quanto a temperature for about 4 months and found the size of the flare-up could be tracked based acceso the heat signature. That means doctors could potentially act early to help patients, rather than wait weeks to controllo blood, tissue, fecal samples.
Now that they’ve found successful results quanto a mice, Sharma and the research team plan to controllo the sensor quanto a human tissues that re-create the inflammatory conditions found quanto a Crohn’s disease. These types of sensors could also be useful for patients with ulcerative colitis, which is another inflammatory bowel disease, other conditions with prolonged inflammatory responses, such as organ transplantation.
“If there is a platform that could monitor the flare-up quanto a real time, this would be significant so the treating physician can take appropriate and timely actions to help remedy the situation,” he said. “With the technological advance that we have described, this could one day become a reality so quality-of-life metrics for those afflicted can be greatly enhanced.”
Caring for Kids
Across the U.S. and Canada, IBD specialists who acceso pediatric patients are working together to find better solutions for kids. Called the CAMEO Study (Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed with Crohn’s Disease), the research aims to understand why some children who receive regolare treatment with anti-tumor necrosis factor (anti-TNF) medications achieve mucosal healing and some don’t.
“Few studies involve Crohn’s therapy quanto a children, and all drugs acceso the market were based acceso large-scale studies quanto a adults,” said Neal LeLeiko, MD, a professor of pediatrics at Columbia University and director of the pediatric IBD program at NewYork-Presbyterian Morgan Stanley Children’s Hospital. LeLeiko is the NewYork-Presbyterian/Columbia site investigator for the CAMEO Study.
A causa di particular, researchers hope to find the best anti-TNF dosing for children, which can vary by weight. As children receive the drug by IV and improve, for instance, they often gain weight, but the prescribed medication dosing may not change, which could then result quanto a a drop quanto a efficacy, LeLeiko explained. A critical part of the study depends acceso a technique known as “therapeutic drug monitoring,” where researchers carefully measure routine bloodwork for the anti-TNF drugs and various aspects of healing.
“I see too many patients who experience failure of anti-TNF drugs paio to previous physicians who didn’t know how to use the drug properly,” he said. “As I always say, ‘If this were my child grandchild, what would I do?’ We need to know how to best use these drugs quanto a children quanto a the safest way.”
